ROBERT F. BETTS, M.D.
This content is PDF only. Please click on the PDF icon to access.
The understanding of the role of cytomegalovirus (CMV) in disease developing after renal transplantation has increased steadily since the initial realization that CMV infection commonly follows transplantation (1). With the recognition that patients acquired primary infection from virus transplanted with the allograft (2, 3) possible methods to prevent allograft-derived infection have been suggested (4, 5). Because morbidity due to cytomegalovirus is less frequent in persons who were antibody-positive before transplantation than in those developing primary infection (6, 7), it seemed logical to test whether vaccine-induced immunity would reduce CMV-associated morbidity. The study reported in this issue by Glazer and colleagues
BETTS RF. Cytomegalovirus Vaccine in Renal Transplants. Ann Intern Med. 1979;91:780–782. doi: https://doi.org/10.7326/0003-4819-91-5-780
Download citation file:
Published: Ann Intern Med. 1979;91(5):780-782.
Infectious Disease, Nephrology, Vaccines/Immunization.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use